Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk is about to launch a mid-stage clinical study with a tablet version of a so-called GLP-1 medicine as it steps up the hunt for diabetes pills that can replace injections.
The Phase II trial may start as early as next week and will involve approximately 600 patients, Chief Science Officer Mads Krogsgaard Thomsen said on Thursday.
"It is a milestone because this is not incremental innovation, it's disruptive innovation," he told Reuters in an interview during a visit to London.
Results of the study are expected in around a year's time.
http://uk.reuters.com/article/2013/11/28/us-novonordisk-diabetes-idUKBRE9AR0LB20131128
The Phase II trial may start as early as next week and will involve approximately 600 patients, Chief Science Officer Mads Krogsgaard Thomsen said on Thursday.
"It is a milestone because this is not incremental innovation, it's disruptive innovation," he told Reuters in an interview during a visit to London.
Results of the study are expected in around a year's time.
http://uk.reuters.com/article/2013/11/28/us-novonordisk-diabetes-idUKBRE9AR0LB20131128